Trials / Completed
CompletedNCT00415623
A Comparative Study Between Amlodipine 10mg And 5mg With Hypertension For Whom 5mg Is Insufficient
A Double-Blind, Comparative Study Between Amlodipine 5mg And 10mg In Patients With Essential Hypertension For Whom Amlodipine 5mg Is Insufficiently Effective
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 305 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 20 Years – 79 Years
- Healthy volunteers
- Not accepted
Summary
The changes in the trough systolic blood pressure from the baseline were assessed after 8 weeks of double-blind treatment with amlodipine 10 mg or amlodipine 5 mg
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Amlodipine | Amlodipine 5mg/ day |
| DRUG | Amlodipine | Amlodipine 10mg/ day |
Timeline
- Start date
- 2007-01-01
- Primary completion
- 2007-10-01
- Completion
- 2007-10-01
- First posted
- 2006-12-25
- Last updated
- 2021-02-11
- Results posted
- 2008-12-09
Locations
14 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00415623. Inclusion in this directory is not an endorsement.